Transforming obesity: The advancement of multi-receptor drugs

May combine two claims.

In that trial, liraglutide-induced weight loss was accompanied by better glucose control, lower systolic and diastolic blood pressure (−2.8 and −0.9 mmHg vs placebo), improved lipid and cholesterol profiles, and a small heart-rate increase of 2.4 beats/min vs placebo.

“In this study, the body weight reduction induced by liraglutide was associated with improved glucose control, a decrease in systolic and diastolic blood pressure (−2.8 and −0.9 mmHg over placebo controls), along with an improvement in lipid and cholesterol profiles; albeit with a slight increase in heart rate of 2.4 beats/min, in comparison to placebo-treated controls67.”

• cites [67] sourceDisputed

  Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

After 32 days of daily cotadutide, subjects with T2D and chronic kidney disease had better postprandial glucose control and greater weight loss, alongside a 51% drop in urinary albumin-to-creatinine ratio.

“Following 32 days of daily treatment, cotadutide further improved postprandial glucose control and potentiated weight loss in subjects with T2D and chronic kidney disease, which was paralleled with a notable 51% reduction in the urinary albumin-to-creatinine ratio98.”

• cites [98] sourceDisputed

  The Abstract describes a three-month trial of vildagliptin or placebo in people with type 2 diabetes, not 32 days of cotadutide in people with type 2 diabetes and chronic kidney disease. The Results report changes in fasting islet-cell responses, not the claimed weight loss or 51% reduction in urinary albumin-to-creatinine ratio. (LLM, conf=0.89)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Activating both GLP-1R and GIPR might improve glucose metabolism via additive effects on insulin and glucagon in the pancreas, and could restore the reduced GIPR sensitivity seen in T2D.

“First, combining GLP-1R and GIPR agonism could further improve glucose metabolism through additive insulinotropic and glucagonostatic action on the pancreas, and potentially even restore the impaired GIPR sensitivity characteristic of T2D119.”

• cites [119] sourceDisputed

  The Introduction identifies IBI362 as a dual GLP-1 and glucagon receptor agonist, not a GLP-1R/GIPR agonist. The Discussion says glucagon receptor activation can cause hyperglycaemia and must be balanced by GLP-1 receptor activity. Our copy does not address restoration of impaired GIPR sensitivity or the claimed additive pancreatic action; no page numbers are available. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

MAR709 completed Phase 1 trials with good tolerability and meaningful drops in body weight and HbA1c in people with T2D.

“MAR709 successfully completed Phase 1 clinical trials with good tolerability48,124,125, concomitant with a meaningful reduction in body weight and HbA1c levels in subjects with T2D48,125.”

• cites [48] sourceNot checked — no full text of the source
• cites [124] sourceNot checked — no full text of the source
• cites [125] sourceDisputed

  The Discussion says MEDI0382 had only recently entered clinical development, rather than completed Phase 1 trials. The reported weight-loss and glucose findings are from mice and monkeys, not people with T2D; the paper does not report human tolerability or HbA1c outcomes. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

In the same Phase 2 study, retatrutide lowered HbA1c levels by approximately 2%, compared with approximately 1.4% for dulaglutide and approximately 0.01% for placebo at the 24-week time point.

“furthermore, the triagonist lowered HbA1c levels by ~2%, compared to ~1.4% or ~0.01% with dulaglutide or placebo, respectively, at the 24 week time point166.”

• cites [166] sourceDisputed

  The Primary Outcome section reports a different trial: tirzepatide versus placebo added to insulin glargine, with HbA1c changes measured at week 40. It gives changes of −2.40% and −2.34% for two tirzepatide doses versus −0.86% for placebo, not the claimed week-24 retatrutide, dulaglutide, and placebo results. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Loss of GCGR signaling can normalize glycemia in insulin-deficient conditions, but only if residual insulin is present.

“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”

• cites [15] sourcePartly supported

  The Results (page unavailable) report that GCGR-knockout mice remained euglycaemic after streptozotocin treatment, unlike wild-type mice. However, streptozotocin did not detectably reduce insulin levels in the knockout mice, so this study does not establish normalization of glycaemia in insulin-deficient knockout mice or test whether residual insulin is required. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [16] sourceSupported
• cites [17] sourceSupported

May combine two claims.

A meta-analysis found that about 56% of weight lost through lifestyle intervention is regained by two years and about 79% by five years.

“This is exemplified by a recent meta-analysis showing that ~56% of body weight loss, as achieved through lifestyle intervention, is regained within two years, and ~79% is regained after five years9.”

• cites [9] sourceSupported

May combine two claims.

Increased GCGR signaling reduces body weight by suppressing food intake and raising energy expenditure, and it alters lipid metabolism by promoting lipolysis and inhibiting lipogenesis.

“Furthermore, enhanced GCGR signaling was reported to effectively reduce body weight through inhibition of food intake20-22 and stimulation of energy expenditure19,22-24, and further, modulate lipid metabolism by driving lipolysis and inhibiting lipogenesis25-28.”

• cites [20] sourceNot checked — no full text of the source
• cites [21] sourceNot checked — no full text of the source
• cites [22]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [19]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [23] sourceNot checked — no full text of the source
• cites [24] sourcePartly supported

  The section “GCGR Agonism as a Weight Loss Partner of GLP-1R Based Therapeutics” says GCGR activation increases energy expenditure and can curb appetite, but describes appetite suppression as a less-established benefit than increased energy use. “Glucagon Induces the Browning of WAT” reports glucagon-stimulated lipid breakdown. The copy does not state that GCGR activation inhibits lipogenesis, so that part of the claim is unsupported. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [25]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [26] sourceNot checked — no full text of the source
• cites [27] sourceNot checked — no full text of the source
• cites [28]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Obesity is a major risk factor for type 2 diabetes, dyslipidemia, cardiometabolic disease, cancer, and death.

“Obesity, characterized by excessive body fat, constitutes a major risk factor for the development of type 2 diabetes (T2D), dyslipidemia, cardiometabolic disease1, cancer2, and overall mortality3.”

• cites [1] sourceSupported
  Experimental — accuracy not yet measured
• cites [2] sourceSupported
  Experimental — accuracy not yet measured
• cites [3] sourceSupported
  Experimental — accuracy not yet measured

May combine two claims.

Central GIPR agonism reduces the emetic effect of GLP-1R agonism and promotes weight loss by suppressing food intake.

“and that central GIPR agonism ameliorates the emetic effect of GLP-1 receptor (GLP-1R) agonism44, and stimulates weight loss through inhibition of food intake45,46.”

• cites [44] sourceCould not verify

  The Abstract and Discussion describe insulin release in rats after GIP was removed from gut extracts; no page numbers are available in our copy. Searches for central GIPR agonism, emesis, food intake, and weight loss found no passage addressing either effect attributed to the source. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [45] sourceNot checked — no full text of the source
• cites [46] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Obesity increases complications from infectious diseases such as COVID-19.

“It further enhances complications associated with infectious diseases, as exemplified by COVID-194.”

• cites [4] sourceSupported

May combine two claims.

GLP-1 has cardiovascular and neuroprotective effects, reduces apoptosis and inflammation, and modulates reward behavior and palatability.

“Beyond its role in glucose metabolism, GLP-1 is known to possess cardio- and neuroprotective effects, reduce cellular apoptosis and inflammation, and modulate reward behavior and palatability8,55 (Figure 1).”

• cites [8] sourcePartly supported

  The Incretin-based therapy section reports improved cardiovascular outcomes with GLP1R agonism in type 2 diabetes, and the Introduction says GLP1R agonists modulate hedonic food intake through brain reward circuits (page numbers unavailable). The passages do not establish neuroprotection or reductions in cellular apoptosis and inflammation; they also do not specifically address palatability. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [55] sourceNot checked — no full text of the source

May combine two claims.

Lifestyle interventions yield about 5-8% short-term weight loss but have limited ability to sustain weight reduction when used alone.

“However, despite appreciable weight loss of ~5-8% in the short term, such lifestyle interventions have only limited potential for sustained weight reduction, particularly when utilized as a stand-alone therapy8.”

• cites [8] sourcePartly supported

  The Introduction (page not provided) says short-term behavioural interventions are frequently insufficient for long-term weight loss and describes lifestyle interventions as moderately effective, supporting the claim about limited sustained benefit when used alone. Our copy does not give the claimed ~5–8% short-term weight-loss figure for lifestyle interventions; the nearby single-digit figures concern drug treatments. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

SAR425899 reduced body weight and fat mass in obese mice, produced glycemic effects in db/db mice, and lowered caloric intake and raised energy expenditure in obese diabetic non-human primates.

“SAR425899 was shown to effectively reduce body weight and fat mass in obese mice, stimulate robust glycemic effects in leptin receptor-deficient diabetic db/db mice, and remarkably, reduce total caloric intake and increase energy expenditure in obese diabetic non-human primates80,83.”

• cites [80] sourceCould not verify

  The Results passage on activation of hypothalamic Gipr-expressing cells describes food-intake experiments in mice, and the STAR★Methods passages describe mouse models and human hypothalamic tissue. Searches for SAR425899, db/db mice, and obese diabetic non-human primates found no passage addressing the attributed drug effects. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [83] sourceCould not verify

  The Animals and housing conditions section lists acyl-GIP, acyl-GLP-1 and MAR709 as the treatments studied, and Fig. 4 reports their effects in mice. Searches for SAR425899, db/db mice and obese diabetic non-human primates found no passage in our copy addressing the attributed results. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

In a Phase 2 trial of obese subjects with T2D, SAR425899 beat liraglutide after 26 weeks for postprandial glycemic control, pancreatic β-cell responsiveness, and insulin sensitivity.

“In a Phase 2 study comprising of obese subjects with T2D, SAR425899 outperformed liraglutide after 26 weeks of treatment, to yield greater improvements in postprandial glycemic control, along with superior pancreatic β-cell responsiveness and enhanced insulin sensitivity84.”

• cites [84] sourceCould not verify

  The Discussion mentions SAR425899 only in a comparison of four-week weight-loss data; it does not report the claimed 26-week trial or comparison with liraglutide. The Glycaemic control section reports results for LY3298176, not SAR425899, and does not establish the claimed differences in β-cell responsiveness or insulin sensitivity. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

First-generation GLP-1R/GCGR co-agonists in animal obesity models produced greater weight loss, better glucose lowering, and reduced food intake than selective GLP-1R agonists.

“Once proven that full potency at each of the two receptors could be chemically assembled into a single chimeric peptide of comparable size to each native hormone, studies in animal models of obesity, utilizing first-generation GLP-1R/GCGR co-agonists, resulted in superior weight loss, enhanced glucose-lowering efficacy, as well as a reduction in food intake, when compared with selective GLP-1R Ag”

• cites [78]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [79] sourceCould not verify

  The Introduction and Results discuss GIPR/GLP-1R co-agonism, including greater weight loss and reduced food intake than GLP-1R agonism alone in mice. They do not report the claimed outcomes for GLP-1R/GCGR co-agonists, or identify those agents as first-generation; a search for glucagon-receptor co-agonism found no supporting passage. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [80] sourcePartly supported

  The Introduction (page unavailable) reports greater weight loss and improved glycemic control versus a GLP-1 receptor agonist, with a possible further reduction in food intake in mice. But it attributes these effects to GLP-1/GIP dual agonism, not the claimed GLP-1R/GCGR co-agonists; it also does not identify them as first-generation agents. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [81] sourceCould not verify

  The Introduction and Discussion discuss GLP-1R agonists and GIPR/GLP-1R combinations, not first-generation GLP-1R/GCGR co-agonists. Searches for GCGR and glucagon-receptor co-agonists found no passage comparing their effects on weight, glucose, or food intake with selective GLP-1R agonists. Page numbers were not available in our copy. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

• AssumptionThe authors state this as an assumption: The benefits of polypharmacotherapy depend on the assumption that the agents will increase weight loss through complementary pharmacology at each target receptor.

May combine two claims.

Cotadutide is a synthetic human oxyntomodulin-based peptide with a palmitic acid side-chain that enables albumin binding and a longer duration of action.

“Cotadutide (also termed MEDI0382) is a synthetic peptide based on human OMX, which employs a palmitic acid side-chain91 that enables albumin binding and thus extension of its duration of action.”

• cites [91] sourceCould not verify

  The supplied passages and additional searches of our copy discuss adiponectin, adipose-tissue metabolism, and potential adiponectin-receptor therapies. They do not address cotadutide or MEDI0382, an oxyntomodulin-based peptide, or a palmitic-acid side-chain used for albumin binding and longer action. The citation therefore cannot be verified from this source. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Cotadutide reduced hepatic steatosis, liver fibrosis, and improved mitochondrial function in murine MASLD models more effectively than liraglutide.

“More recently, cotadutide was shown to alleviate hepatic steatosis, dampen liver fibrosis and improve mitochondrial function in murine models of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), far more effectively than liraglutide93.”

• cites [93] sourceCould not verify

  The Introduction lists MEDI0382 among GLP-1/glucagon coagonists, but does not report its effects on liver disease or compare it with liraglutide. A References entry names a mouse study of a dual agonist and steatohepatitis; it does not establish the claimed cotadutide results. Searches for cotadutide, fibrosis, mitochondrial function, and steatohepatitis found no passage supporting the stated comparison. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Only about 10% of active GLP-1 reaches the general circulation, and only a small fraction of that reaches the brain.

“It is estimated that as little as 10% of active GLP-1 reaches the general circulation, and only a mere fraction of this reaches the brain63.”

• cites [63] sourceCould not verify

  The results passage reports circulating GLP-1 concentrations in control and antibody-treated mice, but not what proportion of active GLP-1 reaches the general circulation. Searches for the 10% estimate and for GLP-1 reaching the brain found no passage addressing either part of the claim (page numbers unavailable). (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

After weekly dosing in diet-induced obese mice, that DPP-4-protected PEGylated peptide lowered body weight and reduced fat mass by about 25.8%, via synergistic anorexia at both receptors and complementary thermogenic and lipolytic GCGR effects.

“The DPP-4-protected peptide carried a 40 kDa polyethylene glycol to delay renal clearance, and after weekly dosing in diet-induced obese mice, the peptide lowered body weight and reduced fat mass by ~25.8%; achieving these effects through the synergistic anorectic action at both target receptors, with complementary thermogenic and lipolytic effects attained through GCGR agonism79.”

• cites [79] sourcePartly supported

  Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

In diet-induced obese rodents, GCGR agonist treatment causes weight loss by reducing food intake, increasing lipid use through brown fat thermogenesis, and raising whole-body energy expenditure, partly via FGF21 and FXR.

“In diet-induced obese rodents, GCGR agonist administration drives weight loss through a reduction in food intake, an induction of lipid utilization via brown fat thermogenesis, along with an increase in whole-body energy expenditure; the latter effect in part attributed to the stimulation of liver-secreted FGF21, and transcriptional upregulation of the hepatic bile acid-activated nuclear receptor,”

• cites [19]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [30] sourceNot checked — no full text of the source
• cites [72] sourceCould not verify

  The Introduction and Discussion address GIP and fat deposition, chiefly in human adipose tissue, not GCGR agonist treatment in diet-induced obese rodents. Searches for GCGR, FGF21, FXR, thermogenesis, food intake, and energy expenditure found no passage addressing the attributed mechanism. Page numbers were not available in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [73] sourceNot checked — no full text of the source

May combine two claims.

Mazdutide is a single-chain synthetic GLP-1R/GCGR co-agonist similar to mammalian oxyntomodulin, with a fatty acyl side-chain that extends its half-life.

“Mazdutide (also termed IBI362, oxyntomodulin 3 (OXM-3) or LY3305677) is a single-chain synthetic GLP-1R/GCGR co-agonist, analogous to mammalian oxyntomodulin (OMX) and modified with a fatty acyl side-chain to extend its circulating half-life86.”

• cites [86] sourceCould not verify

  The Introduction discusses GIPR/GLP-1R co-agonists, and the Discussion describes fatty-acylated GIP analogs, but neither identifies mazdutide or describes a GLP-1R/GCGR co-agonist. Searches for mazdutide and its listed alternative names, oxyntomodulin, and the claimed receptor combination found no passage addressing its structure or half-life. The indexed passages provide section labels but no page numbers. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

May combine two claims.

In Phase 2 trials, cotadutide produced weight loss, greater hepatic lipid lowering, appetite suppression, and reductions in blood pressure and HbA1c in people with obesity and T2D.

“In clinical studies, cotadutide was indeed well tolerated95,96, and in Phase 2 clinical trials, the peptide displayed impressive weight loss efficacy, superior hepatic lipid-lowering capabilities and appetite suppression, along with a reduction in blood pressure and HbA1c levels in individuals with obesity and T2D91,95,97.”

• cites [91] sourceCould not verify

  The supplied passages and searches for cotadutide, Phase 2 trials, and the claimed clinical outcomes found no discussion of cotadutide in this paper. The Abstract passage on reduced hepatic lipid content concerns acid ceramidase in a mouse model, not cotadutide in people with obesity and type 2 diabetes. No passage in our copy establishes the attributed trial results. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [95] sourceNot checked — no full text of the source
• cites [97] sourceNot checked — no full text of the source

May combine two claims.

In obese subjects without T2D, one year of liraglutide produced about 5.2% placebo-corrected weight loss, with roughly one third losing more than 10%.

“In subjects with obesity without T2D, following one year of treatment with liraglutide, ~5.2% placebo-corrected weight loss was achieved, with approximately a third of subjects reaching weight loss of >10%67.”

• cites [67] sourceCould not verify

  The DIO mouse-study Methods and Results describe short-term treatment with REGN1193, not a one-year liraglutide trial in people without T2D. The References section mentions liraglutide only in a cited title. Searches for the 5.2% placebo-corrected loss and the proportion losing more than 10% found no passage reporting those outcomes in our copy; page numbers were unavailable. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Black and Hispanic individuals have a higher burden of T2D and more diabetic complications such as cardiovascular disease.

“Black and Hispanic individuals exhibit a higher burden of T2D90 and higher rates of diabetic complications, such as cardiovascular disease.”

• cites [90] sourceCould not verify

  The citation immediately follows the claim about a higher burden of T2D in Black and Hispanic individuals. The available indexed passages, including the section labeled Abstract (page not specified), provide bibliographic information but no racial or ethnic comparison of T2D burden. Searches for Black, Hispanic, and diabetes prevalence found no passage addressing that comparison. (LLM, conf=0.70)

  Experimental — accuracy not yet measured

May combine two claims.

ALT-801 is a potent, once-weekly balanced co-agonist for GLP-1R and GCGR.

“ALT-801, previously known as SP-1373, is a potent, once weekly balanced co-agonist for GLP-1R and GCGR.”

• cites [100] sourceCould not verify

  The Study Design and Treatments section (p. 2) describes once-daily liraglutide, not ALT-801. Searches for ALT-801, SP-1373, and a once-weekly GLP-1R/GCGR co-agonist found no passage addressing the claim. The paper's different treatment does not establish a contrary finding about ALT-801. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

NN9277's clinical development was discontinued because of adverse effects, especially increased heart rate and impaired glucose tolerance.

“However, its clinical development was eventually discontinued due to adverse effects, most notably increased heart rate and impaired glucose tolerance99.”

• cites [99] sourceCould not verify

  The paper’s section 3.4 discusses discontinuation of MAR709 (NNC0090-2746), not NN9277, and gives a different reason for that decision. Searches for NN9277, increased heart rate, and impaired glucose tolerance found no passage addressing the claimed reason for NN9277’s discontinuation. The copy provides no page number for the section. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

May combine two claims.

In a mouse model of obesity and MASLD, 12 weeks of ALT-801 administration reduced body weight by about 25% and ameliorated hepatic steatosis, inflammation, and fibrosis.

“after 12 weeks of peptide administration in a mouse model of obesity and MASLD, a reduction in body weight by ~25% was apparent, concomitant with an amelioration of hepatic steatosis, inflammation and fibrosis100.”

• cites [100] sourceCould not verify

  The Body Weight section (p. 4) reports weight loss after 56 weeks of liraglutide treatment in people, not after 12 weeks of ALT-801 in mice. Searches for ALT-801, a mouse model, and hepatic steatosis, inflammation, and fibrosis found no passage addressing the attributed result. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

MAR709 resisted breakdown by DPP-4 and had a pharmacokinetic profile that allowed daily dosing in humans.

“The peptide was resistant to DPP-4 proteolysis and displayed a pharmacokinetic profile suitable for daily clinical use124-126.”

• cites [124] sourceNot checked — no full text of the source
• cites [125] sourceCould not verify

  The Introduction describes enhanced stability to peptidase degradation for MEDI0382, not MAR709. Searches for MAR709 and DPP-4 found no passage about MAR709’s proteolytic resistance or a pharmacokinetic profile suitable for daily dosing in humans; the paper’s animal dosing does not establish that clinical claim. Page numbers are unavailable in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [126] sourceNot checked — no full text of the source

May combine two claims.

The frequency of these side effects was 84% and 67% in subjects receiving JNJ-64565111 and 71% and 48% in subjects receiving liraglutide.

“The frequency of these side effects occurred in 84% and 67% of subjects receiving JNJ-64565111 and in 71% and 48% of subjects administered liraglutide101.”

• cites [101] sourceCould not verify

  The Safety and Side-Effect Profile and Table 3 (p. 1000) report adverse-event rates for semaglutide and placebo, not JNJ-64565111 and liraglutide. Searches for JNJ-64565111 and the four cited percentages found no passage reporting those rates for the named drugs. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

In SURPASS-1, at 40 weeks, about 92% of tirzepatide-treated subjects reached HbA1c below 7.0% versus 19% on placebo, and 52% versus 1% reached below 5.7%.

“Following 40 weeks of treatment, ~92% of subjects receiving tirzepatide achieved an HbA1c of <7.0% relative to 19% receiving placebo, with 52% versus 1% of subjects reaching an HbA1c of <5.7%132.”

• cites [132] sourceCould not verify

  The Introduction (page unavailable) mentions tirzepatide only in relation to weight loss. The Results > Pharmacodynamics section (page unavailable) reports HbA1c for NN1177, not tirzepatide. Searches for SURPASS-1, 40 weeks, and the stated HbA1c thresholds and percentages found no passage addressing the claimed comparison. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

Tirzepatide increases glucose uptake in specific tissues, mainly epididymal white fat, brown fat, and skeletal muscle, and this is linked to higher expression of genes for branched-chain amino acid breakdown in brown fat.

“tirzepatide treatment was reported to drive a tissue-specific increase in glucose disposal, preferentially into epididymal white adipose tissue, brown adipose tissue (BAT) and skeletal muscle121; an effect associated with transcriptional upregulation in genes associated with branched chain amino acid catabolism in BAT123,129.”

• cites [121] sourceNot checked — no full text of the source
• cites [123]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [129] sourceCould not verify

  The Introduction and Discussion describe a single-dose study of MEDI0382 in healthy subjects, not tirzepatide. Searches for tissue-specific glucose disposal and branched-chain amino acid catabolism found no passage addressing either claimed effect. Page numbers were not available in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

MAR709 needs CNS GIPR signaling to beat GLP-1R agonism for weight and food intake reduction, but tirzepatide fails to lower body weight in mice lacking Glp1r.

“while MAR709 requires functional GIPR signaling in the CNS to outperform GLP-1R agonism to further reduce body weight and food intake45,127, tirzepatide does not lower body weight in Glp1r-deficient mice121.”

• cites [45] sourceNot checked — no full text of the source
• cites [127] sourceCould not verify

  The Results and Discussion passages address fatty liver disease nomenclature and diagnostic criteria, not drug effects on weight or food intake. Searches for MAR709 and CNS GIPR signaling, and for tirzepatide in Glp1r-deficient mice, found no passage addressing either claim; page numbers were unavailable. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [121] sourceNot checked — no full text of the source

May combine two claims.

In later SURPASS trials, tirzepatide was better than semaglutide 1 mg, insulin degludec, insulin glargine, and insulin lispro at improving glucose control, while maintaining efficacy and safety in people at cardiovascular risk.

“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”

• cites [133] sourceCould not verify

  The Introduction and Discussion describe ALT-801 in a mouse model of NASH, including comparisons with semaglutide; no page number is available in our copy. Searches for tirzepatide, SURPASS, the named insulin comparators, and cardiovascular-risk safety found no passage addressing the attributed claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [134] sourceNot checked — no full text of the source
• cites [135] sourceNot checked — no full text of the source
• cites [136] sourceNot checked — no full text of the source

May combine two claims.

In mouse islets, tirzepatide increases insulin secretion only through GLP-1R, while in human islets it acts mainly through GIPR.

“while tirzepatide promotes insulin secretion in murine islets exclusively via the GLP-1R, the peptide stimulates insulin secretion in human islets predominantly via the GIPR128.”

• cites [128] sourceCould not verify

  The Background and Discussion passages discuss cotadutide, a GLP-1/glucagon receptor agonist, rather than tirzepatide. Searches for tirzepatide and for GIPR-mediated insulin secretion in mouse and human islets found no passage addressing the claimed species-specific mechanism. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

May combine two claims.

Early evidence indicated that tirzepatide caused additional weight loss of 4.3% at 6 months and 7.2% at 12 months, with no difference in gastrointestinal side effects.

“Preliminary evidence further suggested that treatment with tirzepatide led to additional weight loss of −4.3% after 6 months, and −7.2% after 12 months, without differences in the occurrence of gastrointestinal adverse effects149.”

• cites [149] sourceCould not verify

  The Methods describe four weeks of insulin treatment, and the Discussion addresses changes in responses to GLP-1 and GIP. Searches for tirzepatide, the 6- and 12-month weight-loss figures, and gastrointestinal adverse effects found no passage addressing the attributed claim (page numbers unavailable). (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Tirzepatide has also been shown to improve insulin sensitivity, boost β-cell function, and reduce glucose spikes during meal tolerance tests in T2D subjects.

“Recently, tirzepatide treatment was also shown to improve insulin sensitivity, enhance pancreatic β-cell function and slow glucose excursions during meal tolerance tests in T2D subjects148.”

• cites [148] sourceCould not verify

  The Conclusions (page unavailable) mention tirzepatide only in connection with weight reduction in a phase 2 trial. The Methods and Results (page unavailable) examine GIPR antagonists and dulaglutide in mice, not tirzepatide’s effects on insulin sensitivity, β-cell function, or meal-test glucose excursions in people with T2D. Searches for tirzepatide and those outcomes found no passage addressing the claim. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

Together, the SURPASS and SURMOUNT trials confirm that tirzepatide's safety matches GLP-1R agonists and that its efficacy is enhanced at maximum doses of 5, 10, and 15 mg.

“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”

• cites [132] sourcePartly supported

  The Introduction (page unavailable) reports that tirzepatide has demonstrated mean weight loss of up to 19%, supporting the broad point about its efficacy. It does not report SURPASS or SURMOUNT findings, compare tirzepatide’s safety with GLP-1 receptor agonists, or link efficacy to the 5, 10, and 15 mg doses. The trials reported in this paper concern NN1177, not tirzepatide. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [133] sourceCould not verify

  The Introduction and Results describe ALT-801 experiments in mice, not tirzepatide outcomes in the SURPASS or SURMOUNT trials. The References list a tirzepatide-versus-semaglutide study, but our copy does not report the claimed safety comparison or efficacy at 5, 10, and 15 mg (searched: tirzepatide, SURPASS, SURMOUNT, and the doses). (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [134] sourceNot checked — no full text of the source
• cites [135] sourceNot checked — no full text of the source
• cites [136] sourceNot checked — no full text of the source
• cites [143] sourceCould not verify

  The Results sections on GIPR and BMI-associated loci discuss genetic associations and possible links to body-weight regulation, not tirzepatide trials. Searches for SURPASS, SURMOUNT, tirzepatide, GLP-1R agonist comparisons, and the stated doses found no passage addressing the claimed safety or efficacy results. Page numbers were not available in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [145] sourceCould not verify

  The Introduction identifies tirzepatide as a dual GLP-1R/GIPR agonist, and the References list work on SURPASS and a tirzepatide–semaglutide comparison. Neither passage reports combined SURPASS and SURMOUNT findings, comparable safety, or enhanced efficacy at 5, 10, and 15 mg; searches for those trial names, outcomes, and doses found no supporting passage in our copy. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [146] sourceNot checked — no full text of the source
• cites [147] sourceCould not verify

  The Introduction discusses GLP-1 and GIP actions, and the methods describe experiments in mice with incretin receptor agonists. Searches for tirzepatide, SURPASS, SURMOUNT, and the 5, 10, and 15 mg doses found no passage addressing the claimed trial results or safety comparison. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Retatrutide displayed a safety profile not overtly different from selective GLP-1R agonism, with nausea being the most frequently reported adverse effect.

“In these studies, retatrutide displayed a safety profile not overtly different to selective GLP-1R agonism, with some nausea being the most frequently reported adverse effect155,163.”

• cites [155] sourceCould not verify

  The Discussion (page unavailable) discusses gastrointestinal effects of selective GLP-1R agonists and the pharmacology of tirzepatide, but does not report retatrutide safety outcomes. Searches for retatrutide, nausea, and adverse effects found no passage comparing retatrutide’s safety with selective GLP-1R agonism or identifying its most frequent adverse effect. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [163] sourceNot checked — no full text of the source

May combine two claims.

HM15211's metabolic benefits were attributed to its anti-inflammatory properties and its ability to reduce transforming growth factor-β production.

“The latter metabolic benefits were attributed to the peptide’s anti-inflammatory properties and its ability to reduce transforming growth factor-β production154,156.”

• cites [154] sourceCould not verify

  The Results and Discussion passages describe tirzepatide and LAGIPRA, linking improved insulin sensitivity to metabolic changes in brown adipose tissue. Searches for HM15211 and transforming growth factor-β found no passage addressing the claimed anti-inflammatory mechanism or reduced transforming growth factor-β production. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [156] sourceCould not verify

  The Introduction and Discussion describe tirzepatide’s effects on insulin sensitivity and brown-adipose-tissue amino acid metabolism, not HM15211. Searches for HM15211, anti-inflammatory effects, and reduced transforming growth factor-β production found no passage addressing the attributed mechanism. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

HM15211 outperformed liraglutide for weight loss and improved hyperglycemia, increased energy expenditure, lowered hypercholesterolemia, and ameliorated hepatic steatosis and fibrosis in rodent and cynomolgus non-human primate models.

“This triagonist outperformed liraglutide in terms of weight loss, and further, improved hyperglycemia, increased energy expenditure, lowered hypercholesterolemia and ameliorated hepatic steatosis and fibrosis156.”

• cites [156] sourceCould not verify

  The Animal studies section describes tirzepatide treatment in obese mice, not HM15211 treatment in rodents or cynomolgus primates. Searches for HM15211, liraglutide, energy expenditure, hypercholesterolemia, steatosis, and fibrosis found no passage addressing the attributed comparison or outcomes in our copy. (LLM, conf=0.79)

  Experimental — accuracy not yet measured

May combine two claims.

LY3437943 displays balanced activity at GCGR and GLP-1R but enhanced potency at GIPR.

“In contrast to the balanced triagonist MAR423150,151, LY3437943 displayed balanced activity for GCGR and GLP-1R, but enhanced potency at the GIPR.”

• cites [155] sourceCould not verify

  The Discussion describes tirzepatide as a dual GIPR/GLP-1R agonist with greater potency at GIPR than GLP-1R. Searches for LY3437943, GCGR activity, and triagonists found no passage assessing LY3437943 or comparing its potency across all three receptors. The cited paper therefore does not verify the claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

In diet-induced obese mice, LY3437943 lowered body weight by approximately 45%, and this effect was largely preserved at thermoneutrality.

“In diet-induced obese mice, LY3437943 very effectively lowered body weight by ~45%, which was largely preserved at thermoneutrality155.”

• cites [155] sourceCould not verify

  The Introduction discusses weight loss with tirzepatide, but not LY3437943 or a 45% reduction in diet-induced obese mice. The Methods describe mice maintained on standard chow. Searches for LY3437943, thermoneutrality, and the 45% result found no passage addressing the claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

A single 6 mg dose of retatrutide produced weight loss of up to -3.52 kg that persisted for up to 6 weeks.

“A single dose of another triagonist peptide, retatrutide, was shown to elicit impressive weight loss of up to −3.52 kg with a 6 mg dose, which persists for up to 6 weeks155.”

• cites [155] sourceCould not verify

  The Introduction discusses weight loss with tirzepatide, not retatrutide. Searches of our full-text copy for retatrutide, a single 6 mg dose, −3.52 kg, and six weeks found no passage addressing the attributed result. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Retatrutide lowered systolic and diastolic blood pressure, with a subtle increase in heart rate.

“The triagonist further lowered systolic and diastolic blood pressure, with a subtle increase in heart rate155,163.”

• cites [155] sourceCould not verify

  The Introduction discusses tirzepatide’s effects on glucose, weight, and triglycerides, while the Results examine its receptor signaling and insulin secretion; page numbers are unavailable in our copy. Searches for retatrutide, blood pressure, and heart rate found no passage addressing the claimed cardiovascular effects. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [163] sourceNot checked — no full text of the source

May combine two claims.

LY3437943-induced weight loss was accompanied by a reduction in fat mass, a transient suppression of food intake, and marked improvements in glycemic control.

“Weight loss was further accompanied by a reduction in fat mass, a transient suppression in food intake, along with marked improvements in glycemic control155.”

• cites [155] sourcePartly supported

  The Introduction reports weight loss and improved glucose control for tirzepatide (LY3298176), not LY3437943. It does not report a reduction in fat mass or a transient suppression of food intake for LY3437943. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

In healthy subjects, retatrutide caused transient appetite suppression, reduced endogenous glucagon levels, increased systemic β-hydroxybutyrate levels, and improved lipid profile.

“Interestingly, healthy subjects exhibited a transient suppression in appetite, a reduction in endogenous glucagon levels, an increase in systemic β-hydroxybutyrate levels, along with an improved lipid profile155.”

• cites [155] sourceCould not verify

  The Introduction discusses tirzepatide in patients with type 2 diabetes, including lower triglycerides and a proposed appetite-related mechanism. A search of our full-text copy found no retatrutide study in healthy subjects or report of the stated glucagon and β-hydroxybutyrate changes, so it cannot verify the cited sentence. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

In diet-induced obese mice, SAR441255 alleviated hyperglycemia and reduced body weight by approximately 14.1%.

“In diet-induced obese mice, SAR441255 was shown to alleviate hyperglycemia and reduce body weight by ~14.1%;”

• cites [153] sourceCould not verify

  The Abstract reports weight loss with some GIP agonists in rodents, but it does not identify SAR441255 or give a 14.1% reduction. Searches of our copy for “SAR441255” and “14.1%” found no passage addressing this compound’s effects on hyperglycemia or body weight in diet-induced obese mice. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

May combine two claims.

In comparable study populations at 48 weeks, placebo-corrected weight loss was approximately 17% for tirzepatide and approximately 13% for semaglutide.

“In comparison, placebo-corrected weight loss induced by tirzepatide or semaglutide, at this treatment time point in a comparable study population, was ~17%142, and ~13%165, respectively.”

• cites [142] sourceCould not verify

  The Results section reports associations between GIPR variants and body-weight measures, while the Discussion addresses GIPR signaling and obesity; neither gives placebo-corrected treatment outcomes. Searches for tirzepatide, semaglutide, 48 weeks, and the stated percentages found no passage supporting either weight-loss figure. The cited paper has no page numbers in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [165] sourceNot checked — no full text of the source

May combine two claims.

The greater weight loss with LY3437943 was attributed to an increase in energy expenditure that accounted for about 30-35% of the weight lost and was diminished by antibody-based inhibition of GCGR.

“an observation attributed to an increase in energy expenditure, which remarkably accounted for ~30-35% of the weight lost in diet-induced obese mice, and was diminished upon antibody-based inhibition of GCGR155.”

• cites [155] sourceCould not verify

  The Abstract identifies this paper’s subject as tirzepatide (LY3298176), and the Discussion addresses its GIP and GLP-1 receptor activity. Searches of our copy for LY3437943, the 30–35% energy-expenditure figure, and antibody-based GCGR inhibition found no passage reporting the claimed result in diet-induced obese mice. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

The GIPR-blocking antibody conjugated with a GLP-1R agonist showed sustained body weight-lowering efficacy at monthly doses more than a hundred-fold higher than those commonly employed with selective GLP-1 agonists, without gastrointestinal adverse effects.

“The sustained body weight-lowering efficacy at monthly doses that are more than a hundred-fold higher than that commonly employed with selective GLP-1 agonists, without gastrointestinal adverse effects, is difficult to explain.”

• cites [174] sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

In vivo, GIP promotes lipolysis when insulin is normal or low, and mice overexpressing GIP have less fat mass on a high-fat diet.

“However, in vivo, GIP was shown to promote lipolysis under conditions of normo- or hypoinsulinemia, and mice overexpressing GIP exhibit lower fat mass when fed a high-fat diet41.”

• cites [41] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

GIP is secreted by enteroendocrine K-cells in the upper intestine and was first found to be important for the body's response to glucose intake.

“Gut-hormone derived GIP, secreted from enteroendocrine K-cells in the upper intestine in the duodenum and jejunum mucosae32, was initially discovered to play an integral role in the body’s response to glucose intake33,34 (Textbox).”

• cites [32] sourceNot checked — no full text of the source
• cites [33] sourceNot checked — no full text of the source
• cites [34] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Glucagon is implicated in the pathogenesis of type 1 and type 2 diabetes.

“Glucagon, traditionally known for its ability to counteract hypoglycemia, has been implicated in the pathogenesis of type 1 and type 2 diabetes12-14 (Textbox).”

• cites [12] sourceNot checked — no full text of the source
• cites [13] sourceNot checked — no full text of the source
• cites [14] sourceNot checked — no full text of the source

May combine two claims.

Glucagon inhibits gastric motility, increases renal glomerular filtration, and raises heart rate, cardiac contractility, and cardiac output.

“Glucagon also has the ability to inhibit gastric motility29 and promote renal glomerular filtration30, with notable effects evident on the cardiovascular system to increase heart rate, cardiac contractility and cardiac output31 (Figure 1).”

• cites [29] sourceNot checked — no full text of the source
• cites [30] sourceNot checked — no full text of the source
• cites [31] sourceNot checked — no full text of the source

May combine two claims.

Lower caloric intake is often accompanied by reduced energy expenditure and greater sensitivity to factors that stimulate eating.

“A reduction in caloric intake is therefore often accompanied by a decrease in energy expenditure, along with enhanced sensitivity to factors that stimulate food intake10.”

• cites [10] sourceNot checked — no full text of the source

May combine two claims.

In rats, glucagon administration promotes negative energy balance by raising oxygen consumption, an effect later linked to non-shivering thermogenesis.

“Glucagon administration to rats was shown to promote a negative energy balance by increasing oxygen consumption18; an effect later attributed to an increase in non-shivering thermogenesis19.”

• cites [18] sourceNot checked — no full text of the source
• cites [19] sourceNot checked — no full text of the source

May combine two claims.

GIP does not change food intake or body weight in mice with Gipr deleted in the CNS or in GABAergic neurons.

“GIP fails to alter food intake and body weight in mice harboring a deletion of Gipr in either the central nervous system (CNS)45, or more specifically, in γ-aminobutyric acid (GABA)ergic neurons46.”

• cites [45] sourceNot checked — no full text of the source
• cites [46] sourceNot checked — no full text of the source

May combine two claims.

Bariatric surgery was until recently the most effective way to maintain weight reduction and remains the benchmark for anti-obesity drugs.

“Until recently, bariatric surgery had been the most effective treatment for maintaining a reduction in body weight11, and as such, is the current benchmark for anti-obesity medications.”

• cites [11] sourceNot checked — no full text of the source

May combine two claims.

GLP-1 is secreted by enteroendocrine L-cells in the ileum and colon and stimulates insulin, inhibits glucagon secretion, and slows gastric motility.

“The other incretin, GLP-1, secreted from enteroendocrine L-cells in the ileum and colonic mucosae of the large intestine50, was identified for its role in stimulating insulin, inhibiting glucagon secretion and gastric motility; both essential effects in the regulation of glucose homeostasis51-53 (Textbox).”

• cites [50] sourceNot checked — no full text of the source
• cites [51] sourceNot checked — no full text of the source
• cites [52] sourceNot checked — no full text of the source
• cites [53] sourceNot checked — no full text of the source

May combine two claims.

Cotadutide has strong metabolic efficacy in rodents and healthy cynomolgus monkeys, with better weight loss and glucose control than liraglutide.

“Similar to other GLP-1R/GCGR co-agonists, cotadutide displays robust metabolic efficacy in rodents and healthy cynomolgus non-human primates, with superiority in weight loss and glucose control, when compared with the selective GLP-1R agonist liraglutide92.”

• cites [92] sourceNot checked — no full text of the source

May combine two claims.

Poly-pharmacotherapies permit sub-maximal dosing at each receptor, which may improve weight loss through complementary pharmacology and improve tolerability while reducing tachyphylaxis.

“Such poly-pharmacotherapies are designed to allow for individual sub-maximal dosing at each target receptor, and may therefore not only optimize weight loss through complementary pharmacology at several independent receptors, but also improve tolerability while dampening the likelihood of tachyphylaxis.”

• AssumptionThe authors state this as an assumption: The benefits of polypharmacotherapy depend on the assumption that the agents will increase weight loss through complementary pharmacology at each target receptor.

May combine two claims.

GLP-1R agonism is a powerful treatment for T2D and excess adiposity and has favorable cardiovascular and neurodegenerative effects.

“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”

• cites [56] sourceNot checked — no full text of the source
• cites [57] sourceNot checked — no full text of the source
• cites [55] sourceNot checked — no full text of the source

May combine two claims.

GLP-1R/GIPR co-agonists have produced greater weight loss, good safety, and better metabolic outcomes than the best GLP-1R agonists.

“Drugs possessing GLP-1R agonism with complementary pharmacology through the GIPR have yielded astonishing weight loss efficacy, concomitant with an excellent safety profile, and superior metabolic outcomes relative to the best-in-class GLP-1R agonists.”

• AssumptionThe authors state this as an assumption: The benefits of polypharmacotherapy depend on the assumption that the agents will increase weight loss through complementary pharmacology at each target receptor.
• AssumptionThe authors state this as an assumption: The benefits of polypharmacotherapy also depend on the assumption that the positive glycemic and cardiovascular effects of incretins will restrain any potentially detrimental effects of GCGR agonism.

May combine two claims.

Continuous GLP-1 infusion or repeated DPP-4 inhibitor treatment improves glucose metabolism in people with T2D.

“Nonetheless, continuous infusion of GLP-164, or repeated administration of DPP-4 inhibitors65, improve glucose metabolism in subjects with T2D.”

• cites [64] sourceNot checked — no full text of the source
• cites [65] sourceNot checked — no full text of the source

May combine two claims.

Mazdutide reduced food intake and improved glucose tolerance in diet-induced obese and streptozotocin-induced diabetic mice.

“The peptide further reduced food intake and improved glucose tolerance in both diet-induced obese mice and streptozotocin-induced diabetic mice87.”

• cites [87] sourceNot checked — no full text of the source

May combine two claims.

That Phase 1b trial was the first human study to show GLP-1R/GCGR co-agonism could help maintain weight loss and provided clinical support that glucagon agonism contributes to energy balance in obesity.

“This was the first human trial to demonstrate that GLP-1R/GCGR co-agonism could be a suitable option for weight loss maintenance, and further, added clinical validation that glucagon agonism could significantly contribute to the regulation of energy balance in an obese setting (Figure 3).”

• cites [85] sourceNot checked — no full text of the source

May combine two claims.

GCGR is strongly downregulated in chronic kidney disease, and loss of glucagon signaling in the kidney makes it susceptible to fibrosis, inflammation, oxidative stress, and lipid accumulation.

“The GCGR is potently downregulated during chronic kidney disease, and the lack of glucagon signaling in the kidney renders the tissue susceptible to fibrosis, inflammation, oxidative stress and lipid accumulation75.”

• cites [75] sourceNot checked — no full text of the source

May combine two claims.

In diet-induced obese mice, mazdutide lowered body weight, improved glycemic control, and increased energy expenditure, with partial effects retained in mice lacking Glp1r or Gcgr.

“In diet-induced obese mice, mazdutide was reported to lower body weight, improve glycemic control and increase energy expenditure, with partially preserved action evident in mice harboring a deletion of either Glp1r or the Gcgr87.”

• cites [87] sourceNot checked — no full text of the source

May combine two claims.

Mazdutide lowered blood pressure and levels of lipids, blood uric acid, and transaminases, and reduced hepatic lipid accumulation.

“The peptide was further shown to lower blood pressure, reduce lipid, blood uric acid and transaminase levels, and alleviate hepatic lipid accumulation89.”

• cites [89] sourceNot checked — no full text of the source

May combine two claims.

Many gut-hormone combinations have been tested preclinically, several have entered clinical studies, and unimolecular peptides with varying GLP-1R, GIPR, and GCGR activity are the most clinically advanced candidates.

“Multiple gut-hormone combinations have been explored preclinically, with an appreciable number having advanced to clinical studies, with unimolecular peptides possessing varying degrees of GLP-1R, GIPR and GCGR activity, constituting the clinically most matured set of drug candidates.”

May combine two claims.

Mazdutide raised systemic FGF21 and lowered plasma triglycerides.

“Additional metabolic benefits of mazdutide treatment include, but are not limited to, increasing systemic levels of FGF21, and lowering plasma triglyceride levels87.”

• cites [87] sourceNot checked — no full text of the source

May combine two claims.

This first showed that adding GLP-1R/GIPR co-agonism could far exceed GLP-1R mono-agonism, producing more weight loss and better glucose control.

“This highlighted for the first time that supplemental GLP-1R/GIPR co-agonism could greatly outperform GLP-1R mono-agonism, to achieve greater weight loss and elicit further improvements in glucose homeostasis48.”

• cites [48] sourceNot checked — no full text of the source

May combine two claims.

In diet-induced obese mice, MAR709 caused more weight loss and greater food intake suppression than the matched GLP-1 backbone; this advantage disappeared when Gipr was deleted in the CNS or specifically in GABAergic neurons.

“treatment of diet-induced obese mice with MAR709 produced greater weight loss and further suppression in food intake, relative to treatment with the pharmacokinetically-matched GLP-1 backbone; this superiority vanished in mice carrying a deletion of Gipr in the CNS45, or more specifically in GABAergic neurons46.”

• cites [45] sourceNot checked — no full text of the source
• cites [46] sourceNot checked — no full text of the source

May combine two claims.

When Gipr is removed throughout the CNS in mice, GIP no longer suppresses food intake, but GIP-induced weight loss is partly preserved.

“in mice with loss of the Gipr in the CNS at large, the GIP-driven inhibition in food intake is completely diminished, while the GIP-induced weight loss is partially restored45.”

• cites [45] sourceNot checked — no full text of the source

May combine two claims.

This first co-agonist showed better efficacy, lowering blood sugar and stimulating insulin, in diabetic db/db mice, Zucker diabetic fatty rats, and cynomolgus monkeys.

“This co-agonist displayed superior efficacy with anti-hyperglycemic and insulinotropic effects in diabetic db/db mice, Zucker diabetic fatty rats, and cynomolgus non-human primates48.”

• cites [48] sourceNot checked — no full text of the source

May combine two claims.

GIP causes weight loss both by reducing food intake through central actions and by peripheral mechanisms that do not involve food intake.

“This indicates that GIP drives weight loss via central inhibition of food intake, and through non-CNS peripheral mechanisms unrelated to food intake.”

May combine two claims.

Combining GLP-1 and GIP in one molecule might work better than GLP-1 alone, producing more weight loss and greater appetite suppression.

“Second, the physical combination of GLP-1 and GIP could synergize to outperform GLP-1-based mono-agonism, thus yielding greater weight loss with a further reduction in food intake48.”

• cites [48] sourceNot checked — no full text of the source

May combine two claims.

Two unimolecular GLP-1R/GIPR co-agonists, NN0090-2746 and tirzepatide, are the most studied and show better glucose lowering, weight loss, and appetite suppression than similar GLP-1R agonists.

“There are two notable unimolecular GLP-1R/GIPR co-agonist peptides that have been preclinically and clinically most characterized to display enhanced glucose-lowering potential, superior weight loss and appetite suppression, when evaluated with comparable GLP-1R agonists.”

• cites [45] sourceNot checked — no full text of the source
• cites [48] sourceNot checked — no full text of the source
• cites [47] sourceNot checked — no full text of the source

May combine two claims.

The peptide also reduced food intake, lowered fat mass, and improved fatty liver compared with equal doses of either incretin alone.

“The peptide further reduced food intake, decreased fat mass, and ameliorated hepatic steatosis, relative to equimolar dosing with either incretin alone (Figure 2).”

• cites [48] sourceNot checked — no full text of the source

May combine two claims.

Most GLP-1R/GCGR co-agonist peptides have shown strong effects on lowering body weight, improving glucose control, and preserving or restoring metabolic balance.

“In summary, an abundance of preclinical and clinical (Figure 2 and 3) studies actively focus on GLP-1R/GCGR co-agonists, with the majority of peptides displaying an impressive impact on reducing body weight, improving glycemic control, and maintaining or restoring metabolic homeostasis.”

May combine two claims.

In subjects with obesity and T2D, 12 weeks of JNJ-64565111 reduced placebo-corrected body weight by about 7.2%, without notable effects on HbA1c or fasting plasma glucose, but with a reduction in fasting insulin.

“In subjects with obesity and T2D, 12 weeks of JNJ-64565111 treatment reduced placebo-corrected body weight by ~7.2%, however without notable effects on HbA1c levels or fasting plasma glucose levels, albeit with an appreciable reduction in fasting insulin levels102.”

• cites [102] sourceNot checked — no full text of the source

May combine two claims.

In diet-induced obese mice, tirzepatide boosts glucose-dependent insulin release, improves glucose tolerance, suppresses appetite, and causes marked weight loss through increased lipid oxidation in tissues.

“In vivo studies demonstrated that in diet-induced obese mice, tirzepatide enhances glucose-dependent insulin secretion, improves glucose tolerance, stimulates appetite suppression and promotes remarkable weight loss; the latter a result of increased tissue lipid oxidation47 (Figure 2).”

• cites [47] sourceNot checked — no full text of the source

May combine two claims.

A key difference is that MAR709 has balanced activity at GLP-1R and GIPR, while tirzepatide prefers human GIPR over GLP-1R by a 5:1 ratio.

“A critical difference between tirzepatide and MAR709, is that MAR709 displays balanced activity at both GLP-1R and GIPR48,124, whereas tirzepatide favors human GIPR over GLP-1R in a ratio of 5:147.”

• cites [48] sourceNot checked — no full text of the source
• cites [124] sourceNot checked — no full text of the source
• cites [47] sourceNot checked — no full text of the source

May combine two claims.

MAR423 improved dyslipidemia and ameliorated hepatic steatosis in obese mice even at doses with only marginal effects on body weight and satiety.

“MAR423 further improved dyslipidemia and ameliorated hepatic steatosis in obese mice, notably even at doses where the drug only had marginal effects on body weight and satiety152.”

• cites [152] sourceNot checked — no full text of the source

May combine two claims.

In human HEK293 cells, tirzepatide activates both GIPR and GLP-1R signaling, and in isolated human β-cells, it causes more insulin release than GIP or GLP-1 alone.

“in vitro studies in human HEK293 cells revealed that tirzepatide activates both GIPR and GLP-1R signaling, and in isolated human pancreatic β-cells, the tirzepatide-induced insulin secretion was greater, relative to treatment with either GIP or GLP-1 alone47.”